U.S. healthcare regulators approved new sizes of Medtronic's Resolute Integrity drug-eluting stent to treat longer coronary lesions.

Medical device giant Medtronic (NYSE:MDT) won expanded FDA approval for new sizes of its Resolute Integrity drug-eluting stent, the only devices of its kind with regulatory indication for treatment in patients with diabetes.
Concerns that the medical device tax will push companies to lay off workers and move operations...
The FDA clears OrthoSensor's Verasense device, designed to help surgeons fit knee replacement...
ArtVentive Medical Group wins CE Mark approval in the European Union for its EOS peripheral vascular...
The FDA hits Endologix's catheter introducer device recall with Class I status, its most serious...
A blogger's speculation that pSivida might be in line for a buyout bid sends the ophthalmology...